Navigation Links
Substitution of Pixantrone for Doxorubicin in CHOP Chemotherapy Regimen Produces High Rates of Complete Remissions and Long-Term Disease Free Survival in Patients with Relapsed/Refractory Aggressive NHL Who Previously Failed Frontline CHOP Therapy
Date:4/3/2011

SEATTLE, April 4, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today that the April 2011 edition of the peer reviewed journal, Leukemia & Lymphoma (April 2011; 52(4): 620–628) published results of a phase I/II clinical trial evaluating the effect of cyclophosphamide, pixantrone, vincristine, and prednisone ("CPOP") in treating patients with aggressive non-Hodgkin's lymphoma ("NHL") who relapsed following initial therapy with cyclophosphamide, doxorubicin, vincristine (Oncovin), and prednisone ("CHOP").  In the CPOP regimen, pixantrone substitutes for doxorubicin (H) in the CHOP regimen.  Peter Borchmann, M.D., of the University Hospital of Cologne, led the study.  CPOP produced high rates of complete remissions ("CR") and overall response rate ("ORR").  In some patients, these remissions were highly durable despite patients having relapsed after receiving CHOP and other multi-agent therapies.  

The study enrolled 35 patients in the phase I portion of the trial and 30 patients in the phase II portion of the trial. A major tumor response was reported for 80% and 73% of patients in phase I and II respectively, with 57% and 47% of the patients achieving a complete or unconfirmed CR. Median overall survival in the phase II portion of the trial was 17.9 months with four patients achieving notable long-term disease-free survival ranging from 55 to 77 months, despite in some cases having failed multiple prior regimens including stem cell transplantation. High response rates were also observed in the 43% of patients who had received prior rituximab as part of their front-line regimen (CHOP-R), with an ORR rate of 77% and CR rate of 54%. Myelosuppression was the most common toxicity. Side effects (grade 3/4) in phase I of the trial included febrile neutropenia (11%), grade 3/4 infections (3%), and cardiac failure (6%). In phase II of the trial, side effects (grade 3/4) included febril
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDAs Office of New Drugs Meets With Cell Therapeutics on its Appeal on Pixantrone
2. Cell Therapeutics Files Appeal on FDA Decision on New Drug Application (NDA) for Pixantrone to Treat Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma
3. European Medicines Agency Grants Cell Therapeutics Orphan Drug Designation for Pixantrone in Diffuse Large B-Cell Lymphoma (DLBCL)
4. Cell Therapeutics Announces FDAs Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma, February 10, 2010
5. Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines
6. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
7. FDA Sets Action Date of April 23, 2010 for Review of Pixantrone NDA
8. Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
9. Overview of Pixantrone Phase III Clinical Data Presentation at American Society of Clinical Oncology 2009 Annual Meeting Now Available at Clinical Care Options
10. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
11. Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... BEIJING , Sept. 2, 2015 ... or the "Company"), a leading fully integrated plasma-based ... today announced that the Company,s subsidiary Guizhou Taibang ... a strategic collaboration agreement (the "Agreement") with Xinjiang ... raw plasma. The Agreement allows Guizhou Taibang to ...
(Date:9/2/2015)... LAVAL, Quebec , Sept. 2, 2015  Valeant ... VRX) today announced that its affiliate has entered into ... USA , Inc. (NASDAQ: SURG ... to the upfront cash payment, Synergetics stockholders will receive ... if specified sales milestones are achieved following the closing.  ...
(Date:9/2/2015)... Delcath Systems, Inc. (NASDAQ: DCTH ), ... oncology with an emphasis on the treatment of primary ... participate in the upcoming 17 th Annual Rodman ... at the St. Regis Hotel in New York City.  ... and Chief Executive Officer, will present a corporate overview ...
Breaking Medicine Technology:China Biologic Enters into Strategic Collaboration Agreement to Source Raw Materials 2China Biologic Enters into Strategic Collaboration Agreement to Source Raw Materials 3China Biologic Enters into Strategic Collaboration Agreement to Source Raw Materials 4China Biologic Enters into Strategic Collaboration Agreement to Source Raw Materials 5Valeant Pharmaceuticals To Acquire Synergetics USA 2Valeant Pharmaceuticals To Acquire Synergetics USA 3Valeant Pharmaceuticals To Acquire Synergetics USA 4Valeant Pharmaceuticals To Acquire Synergetics USA 5Delcath To Present At The 17th Annual Rodman & Renshaw Conference 2Delcath To Present At The 17th Annual Rodman & Renshaw Conference 3
... CAMBRIDGE, Mass., Oct. 27 Novartis announced today that ... million over the next five years to expand its ... Mass.   "Novartis was the first global ... just a few years ago.  It has achieved prominence ...
... According to Millennium Research Group (MRG), the global ... arthroscope market generated over $30 million in 2010. ... to decreasing scope prices and greater market penetration ... unfavorable economic conditions, manufacturers are being forced to ...
Cached Medicine Technology:Novartis to Expand Global Research Headquarters in Cambridge, MA 2Novartis to Expand Global Research Headquarters in Cambridge, MA 3Novartis to Expand Global Research Headquarters in Cambridge, MA 4Despite Rising Procedure Volumes, the $30 Million European Arthroscope Market Experienced Nominal Growth in 2010 2Despite Rising Procedure Volumes, the $30 Million European Arthroscope Market Experienced Nominal Growth in 2010 3
(Date:9/2/2015)... ... 02, 2015 , ... The Hydration Room, Orange County’s first ... second location this week at 31542 S. Coast Hwy, Suite #4, Laguna Beach, ... for patients to relax while receiving safe and effective therapies. Also offering complimentary ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... companies, has completed a recapitalization with new investment partners Beecken Petty O’Keefe ... Group each offer extensive expertise and connections within the healthcare industry, which ...
(Date:9/2/2015)... ... September 02, 2015 , ... The ... two day international investment and business conference will be hosted at five star ... China. The full-weekend networking conference will feature leading EB-5 industry professionals and Chinese ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... patented products, announces Hand Free Pocket Cop, a safety invention that protects people ... US is worth $31 billion," says Scott Cooper, CEO and Creative Director of ...
(Date:9/2/2015)... ... September 02, 2015 , ... EDAC Systems, Inc., a leading ... and services to both government and commercial clients, today announced the release of ... IBM’s Datacap document capture platform. EDAC PurePAGE processes and enhances the images ...
Breaking Medicine News(10 mins):Health News:The Hydration Room Opens New Location In Laguna Beach, California 2Health News:The Hydration Room Opens New Location In Laguna Beach, California 3Health News:The Hydration Room Opens New Location In Laguna Beach, California 4Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 2Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 3Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 4Health News:The 2015 China Overseas Investment and Entrepreneurship Summit (COIES) Announced 2Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 2Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 3Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 4Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 5Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 6Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 7Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 2Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 3
... for ambulatory care ... ... Cardiac Science,Corporation, (Nasdaq: CSCX ), a leading provider of ... of its HeartCentrix(R) ECG informatics software with Greenway,Medical Technology,s PrimeSuite(R) ...
... to US$5.5 million -, BELLEVILLE, ON, Dec. ... a research-based, technology-driven Canadian,biopharmaceutical company, today announced that ... its long-term convertible debt with Laurus Master,Funds., ... will now have a maximum,borrowing limit of US$5.5 ...
... Upon an ex parte motion,by the Service ... order (TRO) was issued late on Thursday, December ... County, Michigan,enjoining the Michigan Department of Community Health, ... Carlyle Group from taking certain actions related to,completing ...
... 20 Percent of Cost for New Hospital, SAN ... has reached its $50 million Capital Campaign,goal, the largest ... recent gift of $500,000 from the Stephen and Mary ... http://www.newscom.com/cgi-bin/prnh/20071220/DC10448 ), "It,s only fitting that ...
... For ... Breast Cancer Research., NEWPORT NEWS, Va., Dec. 20 ... Inc. of San Diego,California have settled their lawsuit over Dilon,s ... Dilon in the U.S.,District Court for the Southern District of ...
... gives DRAXIMAGE strong competitive position ... MONTREAL, Dec. 20 /PRNewswire-FirstCall/ - DRAXIMAGE, the,radiopharmaceutical ... (NASDAQ:,DRAX), has appointed GE Healthcare, an industry ... of DRAXIMAGE(R) Sestamibi in the United,States. DRAXIMAGE(R) ...
Cached Medicine News:Health News:Cardiac Science Announces HeartCentrix(R) ECG Informatics Connectivity With Greenway(R) Medical Technologies 2Health News:Cardiac Science Announces HeartCentrix(R) ECG Informatics Connectivity With Greenway(R) Medical Technologies 3Health News:Cardiac Science Announces HeartCentrix(R) ECG Informatics Connectivity With Greenway(R) Medical Technologies 4Health News:Bioniche Amends Terms of Convertible Debt with Laurus Master Funds 2Health News:Manor Care To Vigorously Contest TRO 2Health News:Sharp HealthCare Foundation Reaches $50 Million Goal 2Health News:Sharp HealthCare Foundation Reaches $50 Million Goal 3Health News:DRAXIS Names GE Healthcare as Exclusive Distributor of DRAXIMAGE(R) Sestamibi in USA 2Health News:DRAXIS Names GE Healthcare as Exclusive Distributor of DRAXIMAGE(R) Sestamibi in USA 3Health News:DRAXIS Names GE Healthcare as Exclusive Distributor of DRAXIMAGE(R) Sestamibi in USA 4Health News:DRAXIS Names GE Healthcare as Exclusive Distributor of DRAXIMAGE(R) Sestamibi in USA 5Health News:DRAXIS Names GE Healthcare as Exclusive Distributor of DRAXIMAGE(R) Sestamibi in USA 6Health News:DRAXIS Names GE Healthcare as Exclusive Distributor of DRAXIMAGE(R) Sestamibi in USA 7
... Accurately tests for Nystagmus when ... 10" high by 8" diameter. Light ... ball bearings for effortless spin mechanism. ... from patient. Includes both Adult and ...
Diagnose dry eye, assess the effectiveness of permanent punctal occlusion, collagen - dissolvable in 3-5 days, all are 2 mm long. Sterile...
Clear Base Stand Magnifiers are ideal for any visual task that requires high magnification....
Contour design eyelid implants....
Medicine Products: